Indivior Pharmaceuticals, Inc. (INDV)

NASDAQ: INDV · Real-Time Price · USD

39.59

+0.51 (1.31%)

Aug 18, 2026, 1:19 PM EDT - Market open

Indivior Pharmaceuticals Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,331	1,239	1,188	1,093	901	791
Revenue Growth	13.47%	4.29%	8.69%	21.31%	13.91%	22.26%
Gross Profit	1,141	1,041	998	919	750	664
Operating Income	567	387	296	247	215	187
Net Income	356	210	7	-126	-44	205
Earnings Per Share	2.77	1.64	0.05	-0.92	-0.32	1.35
EPS Growth	227.70%	3180.00%	-	-	-	-

Revenue by Geography

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
United States	1,147	1,053	1,008	912	732	603
Rest of World	184	186	179	181	169	181
Total	1,331	1,239	1,187	1,093	901	791

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	222	195	320	410	893	1,102
Total Debt	509	351	375	283	277	286
Net Cash (Debt)	-287	-156	-55	127	616	816
Net Cash Growth	-	-	-	-79.38%	-24.51%	42.41%
Net Cash Per Share	-2.22	-1.22	-0.41	0.93	4.43	5.37

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-40	-27	36	-300	-4	353
Capital Expenditures	-71	-66	-29	-8	-5	-4
Free Cash Flow	-111	-93	7	-308	-9	349
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	85.72%	84.02%	84.01%	84.08%	83.24%	83.94%
Operating Margin	42.60%	31.24%	24.92%	22.60%	23.86%	23.64%
Pretax Margin	29.60%	19.29%	1.68%	-13.27%	-9.77%	24.02%
Profit Margin	26.75%	16.95%	0.59%	-11.53%	-4.88%	25.92%
FCF Margin	-8.34%	-7.51%	0.59%	-28.18%	-1.00%	44.12%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 18, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	14.12	21.33	221.91	-	-	11.82
Forward PE	8.44	12.78	8.55	8.96	17.02	17.57
P/FCF Ratio	-	-	221.91	-	-	6.94
PS Ratio	3.47	3.62	1.31	1.91	3.30	3.06